Alluvi, formerly LY3414901, represents a significant advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist demonstrates remarkable impact in early medical data, with impressive slimming observed